MAPT and Alzheimer disease: Since low levels of acetylcholine and abnormal levels of Aβ, tau protein aggregation, inflammation and oxidative stress are all features believed to be associated with AD, research has focused on the cholinergic system and primarily on acetylcholinesterase (AChE) inhibitors [78,79,80].